International Journal of Hematology

, Volume 76, Supplement 1, pp 386–392 | Cite as

The role of the EBMT activity survey in the management of hematopoietic stem cell transplantation

  • Alois Gratwohl
Current Status and Future Direction of International Registries

Abstract

Disease or treatment oriented registries form an integral part of modern medicine. They complement industry driven, corporate group sponsored and institutional research and are, together with prospective randomised trials cornerstones of modern evidence based medicine. Focus has been on rapid collection, analysis and dissemination of information on rare procedures with stress on patient outcome. In complex expensive procedures, such as hematopoietic stem cell transplants (HSCT), novel structures are required to catch outcome at team or national level. The annual activity survey of the European Group for Blood and Marrow Transplants EBMT forms such an instrument. Since 1990, EBMT has been collecting, on an annual basis, numbers of HSCT from the preceding year according to indication, donor type and stem cell source. The survey covers all European countries. In 1990, 143 teams reported 4,234 HSCT; in the year 2000, 619 teams reported 19,136 HSCT (33% allogeneic, 67% autologous). This information, which covers over 90% of all HSCT performed in Europe and is based on 132,963 HSCT (33% allogeneic, 67% autologous), gives a clear overview of current status and ongoing trends. It shows the general increase in HSCT from 1990 to 2000 with few exceptions, such as autologous HSCT for breast cancer and allogeneic HSCT for chronic myeloid leukemia. It illustrates the shift in technology from bone marrow as stem cell source in 1990 (100%) to peripheral blood in 2000 (96% of autologous, 53% of allogeneic HSCT). Supplemented by population data and economic factors (Gross national Product, Health Care Expenditures, Health Care systems) of the individual countries it allows comparison of transplant rates (Number of transplants per 10 million inhabitants), team densities (Number of transplant teams per 10 million inhabitants) and trends between countries. It permits quantification of the impact of economics and health care systems and provides a basis for quality control and allows assessment of the main factors influencing team decisions: evidence, disease prevalence, economics and expectations. As such, it is an essential tool for patient counselling and health care planning.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT).Bone Marrow Transplant 1991;8:197–201.PubMedGoogle Scholar
  2. 3.
    Gratwohl A, Baldomero H, Hermans J. Quantitative assessment of consensus on indications for blood or marrow transplantation in Europe 1995.Cancer Research Therapy and Control 1999;10:123–144.Google Scholar
  3. 3.
    Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Economics, health care systems and utilisation of haematopoietic stem cell transplants in Europe.Br J Haematol 2002; 117:451–468.PubMedCrossRefGoogle Scholar
  4. 4.
    Forman SJ, Blume KG, Thomas ED (Eds.): Hematopoietic cell transplantation, Second edition, Blackwell Scientific Publishers Inc., London, New York; 1998.Google Scholar
  5. 5.
    Lennard AL, Jackson GH. Stem cell transplantation.BMJ 2000;321:433–437.PubMedCrossRefGoogle Scholar
  6. 6.
    Goldman JM, Schmitz N, Niethammer D, Gratwohl A for the Accreditation Subcommittee of the EBMT. Special Report. Allogeneic and autologous transplantation for hematological diseases, solid tumours and immune disorders: current practice in Europe in 1998.Bone Marrow Transplant 1998;21:1–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors.N Engl J Med 1997;337:373–381.PubMedCrossRefGoogle Scholar
  8. 8.
    Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.N Engl J Med 2001;344:175–181.PubMedCrossRefGoogle Scholar
  9. 9.
    Confer DL. Unrelated marrow donor registries.Curr Opin Hematol 1997;4:408–412.PubMedCrossRefGoogle Scholar
  10. 10.
    Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley JF, Gorin NC, Szer J, Bradstock K, Buzyn A, Clark P, Borkett K, Gratwohl A for the European Group for Blood and Marrow Transplanation (EBMT).Blood (in press).Google Scholar
  11. 11.
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects.Blood, 2001;97:3390–3400.PubMedCrossRefGoogle Scholar
  12. 12.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med 2001;344:1038–1042.PubMedCrossRefGoogle Scholar
  13. 13.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med 2001;344:1031–1037.PubMedCrossRefGoogle Scholar
  14. 14.
    Gratwohl A, Baldomero H, Urbano-Ispizua A. Hematopoietic stem cell transplantation and Gleevec: anticipation as driving force in decision making.Lancet 2002;359:712–713.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Alois Gratwohl
    • 1
  1. 1.Division of Hematology, Department of Internal MedicineKantonsspital BaselSwitzerland

Personalised recommendations